The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 30, 2014

Filed:

Jun. 03, 2014
Applicant:

Sareum Limited, Cambridge, GB;

Inventors:

John Charles Reader, Linton, GB;

John Mark Ellard, Royston, GB;

Helen Boffey, Debden, GB;

Susanne Taylor, Cambridge, GB;

Andrew David Carr, Great Chesterford, GB;

Michael Cherry, Haddenham, GB;

Michelle Wilson, Cambridge, GB;

Richard Boakye Owoare, London, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 263/34 (2006.01); C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 451/02 (2006.01); C07D 453/02 (2006.01); C07D 263/48 (2006.01);
U.S. Cl.
CPC ...
C07D 263/48 (2013.01); C07D 453/02 (2013.01); C07D 413/10 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 413/12 (2013.01); C07D 451/02 (2013.01); C07D 263/34 (2013.01);
Abstract

The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Aris a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R; ArJs a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R; and Rand Rare as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.


Find Patent Forward Citations

Loading…